Sunitinib

Summary

Sunitinib (CHEMBL535) is an approved small-molecule angiogenesis inhibitor (ATC L01EX01) targeting LATS1, LATS2, and PDGFRB; indicated across 66 conditions including neoplasm and renal cell carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01EX01
• Targets: 9 (LATS1, LATS2, PDGFRB…)
• Indications: 66 conditions
• Clinical trials: 301
• Chemistry: 398.5 Da · C22H27FN4O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL535
Name	Sunitinib
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	5329102
ChEBI	CHEBI:38940
ATC	L01EX01
Molecular formula	C22H27FN4O2
Molecular weight	398.5
InChIKey	WINHZLLDWRZWRT-ATVHPVEESA-N

SMILES: CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C

IUPAC name: N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide

Pharmacological roles (ChEBI): angiogenesis inhibitor, antineoplastic agent, EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, vascular endothelial growth factor receptor antagonist, immunomodulator, neuroprotective agent.

Also known as: NSC-736511, NSC-750690, SU-011248, SU-11248, SU011248, Sunitinib, Sunitinib accord, sunitinib, sutent, SID26758053, su11248, Sutent

Parent form; salt/anhydrous children: CHEMBL1567, CHEMBL3109278, CHEMBL3542310

Patent coverage: 19,507 distinct patent families (79,020 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
LATS1	large tumor suppressor kinase 1	Inhibition	6.2	0.1%	O95835
LATS2	large tumor suppressor kinase 2	Inhibition	6.34	0.6%	Q9NRM7
PDGFRB	platelet derived growth factor receptor beta	Inhibition	8.1	2.3%	P09619
KIT	KIT proto-oncogene, receptor tyrosine kinase	Inhibition	7.88	0.5%	P10721
FLT3	fms related receptor tyrosine kinase 3	Inhibition	8.19	0.9%	P36888
FGFR1	fibroblast growth factor receptor 1	Inhibition	6.08	11.5%	P11362
KDR	kinase insert domain receptor	Inhibition	7.65	1.1%	P35968
FLT4	fms related receptor tyrosine kinase 4	Inhibition	8.05	0.2%	P35916
RET	ret proto-oncogene	Inhibition	8.8	0.4%	P07949

Broader ChEMBL bioactivity targets: 346 (assay-derived). Sample: Leucine-rich repeat serine/threonine-protein kinase 2, Rhodopsin kinase GRK7, Serine/threonine-protein kinase 38, Homeodomain-interacting protein kinase 4, Pyridoxal kinase, Serine/threonine-protein kinase/endoribonuclease IRE1, Serine/threonine-protein kinase OSR1, STE20/SPS1-related proline-alanine-rich protein kinase, Mitogen-activated protein kinase kinase kinase 13, Serine/threonine-protein kinase ICK.

Bioactivity

ChEMBL activities: 1,272 potent at pChembl ≥ 5 of 1,306 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PDGFRB	10.12	Kd	0.07	nM	CHEMBL_ACT_2899097
PDGFRB	10.12	Kd	0.07	nM	CHEMBL_ACT_3449299
PDGFRB	10.12	Kd	0.07	nM	CHEMBL_ACT_7570623
KDR	9.7	Kd	0.2	nM	CHEMBL_ACT_2206802
PDGFRB	9.7	Kd	0.2	nM	CHEMBL_ACT_2206808
PDGFRB	9.68	Kd	0.21	nM	CHEMBL_ACT_1650264
KIT	9.68	Kd	0.21	nM	CHEMBL_ACT_2897017
KIT	9.68	Kd	0.21	nM	CHEMBL_ACT_3449246
KIT	9.68	Kd	0.21	nM	CHEMBL_ACT_7570540
FLT3	9.66	Kd	0.22	nM	CHEMBL_ACT_3449191
FLT3	9.66	Kd	0.22	nM	CHEMBL_ACT_7570689
KDR	9.64	Kd	0.23	nM	CHEMBL_ACT_1650273
KIT	9.55	Kd	0.28	nM	CHEMBL_ACT_2896979
KIT	9.55	Kd	0.28	nM	CHEMBL_ACT_3449243
KIT	9.55	Kd	0.28	nM	CHEMBL_ACT_7570539
KIT	9.43	Kd	0.37	nM	CHEMBL_ACT_2895955
KIT	9.43	Kd	0.37	nM	CHEMBL_ACT_3449231
KIT	9.43	Kd	0.37	nM	CHEMBL_ACT_6220459
KIT	9.43	Kd	0.37	nM	CHEMBL_ACT_7569010
KDR	9.4	IC50	0.4	nM	CHEMBL_ACT_24867119
KIT	9.39	Kd	0.41	nM	CHEMBL_ACT_2897830
KIT	9.39	Kd	0.41	nM	CHEMBL_ACT_3449240
KIT	9.39	Kd	0.41	nM	CHEMBL_ACT_7570538
FLT3	9.39	Kd	0.41	nM	CHEMBL_ACT_7570685
FLT3	9.37	Kd	0.43	nM	CHEMBL_ACT_19250423
FLT3	9.33	Kd	0.47	nM	CHEMBL_ACT_2907411
FLT3	9.33	Kd	0.47	nM	CHEMBL_ACT_2929986
FLT3	9.33	Kd	0.47	nM	CHEMBL_ACT_3446534
FLT3	9.33	Kd	0.47	nM	CHEMBL_ACT_3449179
KIT	9.15	IC50	0.7	nM	CHEMBL_ACT_13370874

Target pathways

Aggregated over 9 target gene(s): LATS1, LATS2, PDGFRB, KIT, FLT3, FGFR1, KDR, FLT4, RET.

Top Reactome pathways

94 total, by targets touching each:

Pathway	Targets	Genes
RAF/MAP kinase cascade	5	FGFR1, FLT3, KIT, PDGFRB, RET
PIP3 activates AKT signaling	4	FGFR1, FLT3, KIT, PDGFRB
Constitutive Signaling by Aberrant PI3K in Cancer	4	FGFR1, FLT3, KIT, PDGFRB
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	4	FGFR1, FLT3, KIT, PDGFRB
Signal Transduction	3	KIT, LATS1, LATS2
PI3K Cascade	2	FGFR1, FLT3
VEGF binds to VEGFR leading to receptor dimerization	2	FLT4, KDR
Signaling by Hippo	2	LATS1, LATS2
High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells	2	FLT4, KDR
Developmental Biology	1	KIT
Signaling by SCF-KIT	1	KIT
Regulation of KIT signaling	1	KIT
Disease	1	KIT
Signaling by FGFR1 amplification mutants	1	FGFR1
Signaling by activated point mutants of FGFR1	1	FGFR1
Downstream signal transduction	1	PDGFRB
Signaling by PDGF	1	PDGFRB
FGFR1b ligand binding and activation	1	FGFR1
FGFR1c ligand binding and activation	1	FGFR1
FGFR1c and Klotho ligand binding and activation	1	FGFR1
Neuropilin interactions with VEGF and VEGFR	1	KDR
Negative regulation of the PI3K/AKT network	1	KIT
Generic Transcription Pathway	1	KIT
Integrin cell surface interactions	1	KDR
PI3K/AKT Signaling in Cancer	1	KIT
NCAM signaling for neurite out-growth	1	FGFR1
VEGFA-VEGFR2 Pathway	1	KDR
Signal transduction by L1	1	FGFR1
VEGFR2 mediated cell proliferation	1	KDR
Phospholipase C-mediated cascade: FGFR1	1	FGFR1

Dominant GO biological processes

GO term	Targets
protein phosphorylation	9
cell surface receptor protein tyrosine kinase signaling pathway	6
positive regulation of cell population proliferation	6
protein autophosphorylation	6
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	6
cell migration	6
positive regulation of MAPK cascade	6
peptidyl-tyrosine phosphorylation	5
positive regulation of cell migration	5
angiogenesis	4
signal transduction	3
positive regulation of MAP kinase activity	3
positive regulation of ERK1 and ERK2 cascade	3
hemopoiesis	3
positive regulation of macromolecule metabolic process	3

Indications & clinical

Indications

66 indications (9 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
renal cell carcinoma	4	MONDO:0005086	EFO:0000681
clear cell renal carcinoma	4	MONDO:0005005	EFO:0000349
pancreatic neuroendocrine tumor	4	MONDO:0019954	EFO:1000045
neuroendocrine neoplasm	4	MONDO:0019496	EFO:1001901
papillary renal cell carcinoma	4	MONDO:0017884	EFO:0000640
gastrointestinal stromal tumor	4	MONDO:0011719	MONDO:0011719
renal cell adenocarcinoma	4	MONDO:0005549	EFO:0005708
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
metastatic prostate carcinoma	3	MONDO:0004956	EFO:0000196
breast neoplasm	3	MONDO:0021100	EFO:0003869
prostate adenocarcinoma	3	MONDO:0005082	EFO:0000673
kidney cancer	3	MONDO:0002367	MONDO:0002367
kidney neoplasm	3	MONDO:0021163	EFO:0003865
urinary bladder neoplasm	2	MONDO:0004987	EFO:0000294
head and neck squamous cell carcinoma	2	MONDO:0010150	EFO:0000181
hepatocellular carcinoma	2	MONDO:0007256	EFO:0000182
adenocarcinoma	2	MONDO:0004970	EFO:0000228
melanoma	2	MONDO:0005105	EFO:0000756
metastatic melanoma	2	MONDO:0005191	EFO:0002617
thymoma	2	MONDO:0006456	EFO:1000581
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
glioblastoma	2	MONDO:0018177	EFO:0000519
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
gastric neoplasm	2	MONDO:0021085	EFO:0003897
thyroid gland carcinoma	2	MONDO:0015075	EFO:0002892
sarcoma	2	MONDO:0005089	EFO:0000691
cholangiocarcinoma	2	MONDO:0019087	EFO:0005221
carcinoma	2	MONDO:0004993	EFO:0000313
germ cell tumor	2	MONDO:0005040	EFO:0000514
colorectal neoplasm	2	MONDO:0005335	EFO:0004142
carcinoid tumor	2	MONDO:0005369	EFO:0004243
alveolar soft part sarcoma	2	MONDO:0011655	EFO:0007143
pancreatic endocrine carcinoma	2	MONDO:0005893	EFO:0007416
colorectal carcinoma	2	MONDO:0024331	EFO:1001951
soft tissue sarcoma	2	MONDO:0018078	EFO:1001968
urothelial carcinoma	2	MONDO:0040679	EFO:0008528
fallopian tube carcinoma	2	MONDO:0006206	EFO:1000251
thymic carcinoma	2	MONDO:0006451	EFO:1000576
adrenal cortex carcinoma	2	MONDO:0006639	EFO:1000796
adrenal gland pheochromocytoma	2	MONDO:0004974	EFO:0000239
peritoneal neoplasm	2	MONDO:0006901	MONDO:0002087
fallopian tube neoplasm	2	MONDO:0021092	MONDO:0002158
ovarian cancer	2	MONDO:0008170	MONDO:0008170
lung neoplasm	2	MONDO:0021117	MONDO:0008903
brain neoplasm	2	MONDO:0021211	EFO:0003833
von Hippel-Lindau disease	2	MONDO:0008667	MONDO:0008667
thymus neoplasm	2	MONDO:0005197	EFO:0002626
uveal melanoma	2	MONDO:0006486	EFO:1000616
nasopharyngeal carcinoma	2	MONDO:0015459	MONDO:0015459
glioma	2	MONDO:0021042	MONDO:0100342
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
Ebola hemorrhagic fever	1	MONDO:0005737	EFO:0007243
gliosarcoma	1	MONDO:0016681	EFO:1001465
osteosarcoma	1	MONDO:0009807	EFO:0000637
kidney disorder	1	MONDO:0005240	EFO:0003086

10 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 301.

Phase distribution

Phase	Trials
PHASE2	155
PHASE1	45
Not specified	39
PHASE3	33
PHASE1/PHASE2	20
PHASE4	6
EARLY_PHASE1	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00930345	PHASE4	TERMINATED	Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
NCT01402089	PHASE4	COMPLETED	Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
NCT01525550	PHASE4	COMPLETED	A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
NCT02555748	PHASE4	COMPLETED	Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma
NCT02691793	PHASE4	COMPLETED	Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors
NCT05949424	PHASE4	UNKNOWN	OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
NCT02811861	PHASE3	ACTIVE_NOT_RECRUITING	Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
NCT03091192	PHASE3	ACTIVE_NOT_RECRUITING	Savolitinib vs. Sunitinib in MET-driven PRCC.
NCT03141177	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
NCT03673501	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
NCT03768063	PHASE3	ACTIVE_NOT_RECRUITING	A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NCT04523272	PHASE3	ACTIVE_NOT_RECRUITING	A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
NCT05043090	PHASE3	ACTIVE_NOT_RECRUITING	Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
NCT05208047	PHASE3	ACTIVE_NOT_RECRUITING	(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
NCT05477576	PHASE3	RECRUITING	Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT05734105	PHASE3	ACTIVE_NOT_RECRUITING	A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
NCT07165418	PHASE3	NOT_YET_RECRUITING	A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI
NCT07218926	PHASE3	RECRUITING	A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT00075218	PHASE3	COMPLETED	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)
NCT00083889	PHASE3	COMPLETED	SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
NCT00373256	PHASE3	COMPLETED	A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer
NCT00435409	PHASE3	COMPLETED	A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer
NCT00457392	PHASE3	COMPLETED	A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
NCT00457691	PHASE3	COMPLETED	Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer
NCT00676650	PHASE3	TERMINATED	Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
NCT00720941	PHASE3	COMPLETED	Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma
NCT00732914	PHASE3	COMPLETED	Sequential Study to Treat Renal Cell Carcinoma
NCT00930033	PHASE3	COMPLETED	Clinical Trial to Assess the Importance of Nephrectomy
NCT01064310	PHASE3	COMPLETED	Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer
NCT01265901	PHASE3	COMPLETED	IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
NCT01694277	PHASE3	COMPLETED	Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
NCT02231749	PHASE3	COMPLETED	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02420821	PHASE3	COMPLETED	A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)
NCT02684006	PHASE3	COMPLETED	A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)
NCT02853331	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
NCT03025893	PHASE2/PHASE3	UNKNOWN	A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme
NCT03260894	PHASE3	COMPLETED	Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
NCT03729245	PHASE3	TERMINATED	A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator’s Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
NCT04394975	PHASE3	COMPLETED	Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
NCT04409223	PHASE3	TERMINATED	Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 16 clinical and 138 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

274 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
Afatinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Axitinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Crizotinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Fedratinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
MIDOSTAURIN	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Pazopanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Sorafenib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Vandetanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
NINTEDANIB	ChEMBL	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
DOVITINIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
LESTAURTINIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
LINIFANIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
SU-014813	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
TOZASERTIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Selumetinib	PubChem	Approved	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Erlotinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
Gefitinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, LATS2, RET
Quizartinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, FLT4, KDR, KIT, LATS1, LATS2, PDGFRB, RET
REGORAFENIB	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, PDGFRB, RET
Tivozanib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, PDGFRB, RET
R-406	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, LATS2, PDGFRB, RET
Idelalisib	PubChem	Approved	FGFR1, FLT3, FLT4, KIT, LATS1, LATS2, PDGFRB, RET
Cabozantinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, RET
Entrectinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, LATS1, RET
Lenvatinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT4, KDR, KIT, LATS1, PDGFRB, RET
Ponatinib	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, KDR, KIT, LATS1, PDGFRB, RET
CEDIRANIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
MOTESANIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
SEMAXANIB	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
CENISERTIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
DORAMAPIMOD	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
FORETINIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
ILORASERTIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
MILCICLIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KIT, LATS1, PDGFRB, RET
RAF-265	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB, RET
Bosutinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, KIT, LATS1, LATS2, PDGFRB, RET
Imatinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, KDR, KIT, LATS1, LATS2, PDGFRB
Nilotinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, KIT, LATS1, LATS2, PDGFRB, RET
BRIGATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, RET
DASATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FLT3, KDR, KIT, PDGFRB, RET
INFIGRATINIB	ChEMBL	Phase 4 (approved)	FGFR1, FLT3, FLT4, KDR, KIT, RET
BRIVANIB	ChEMBL	Phase 3	FGFR1, FLT4, KDR, KIT, PDGFRB, RET
ORANTINIB	ChEMBL	Phase 3	FGFR1, FLT3, KDR, LATS1, PDGFRB, RET
RUBOXISTAURIN	ChEMBL	Phase 3	FGFR1, FLT3, KIT, LATS1, LATS2, PDGFRB
AT-9283	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, LATS1, RET
DANUSERTIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, RET
DEFOSBARASERTIB	ChEMBL	Phase 2	FLT3, FLT4, KDR, KIT, PDGFRB, RET
MK-2461	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, PDGFRB, RET
OSI-632	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, PDGFRB, RET
REBASTINIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, RET
TANDUTINIB	ChEMBL	Phase 2	FGFR1, FLT3, FLT4, KDR, KIT, PDGFRB
Binimetinib	PubChem	Approved	FGFR1, FLT3, KDR, LATS1, PDGFRB, RET
Ceritinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, KDR, KIT, LATS1, RET
FOSTAMATINIB	ChEMBL + PubChem	Phase 4 (approved)	FGFR1, FLT3, LATS1, PDGFRB, RET
Pexidartinib	ChEMBL + PubChem	Phase 4 (approved)	FLT3, KDR, KIT, LATS1, PDGFRB
BARASERTIB	ChEMBL	Phase 3	FLT3, KDR, KIT, PDGFRB, RET
CANERTINIB	ChEMBL	Phase 3	FLT3, KDR, KIT, PDGFRB, RET
ENZASTAURIN	ChEMBL	Phase 3	FGFR1, FLT3, FLT4, KIT, PDGFRB
SARACATINIB	ChEMBL	Phase 3	FLT3, KDR, KIT, PDGFRB, RET
VATALANIB	ChEMBL	Phase 3	FLT4, KDR, KIT, PDGFRB, RET